An update on two trials evaluating venetoclax in subsets of CLL
How combining an evolutionary perspective with genomic methods can advance CLL treatment
The IFM 2012-03 trial: what will the next step be?
Smouldering myeloma: detection, risk stratification and defining a new standard of care
Clinical evidence supporting rituximab
Won Seog Kim